Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators

Target: CX3CR1 Composite Score: 0.563 Price: $0.56▲9.6% Citation Quality: Pending neurodegeneration Status: debated

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🔥 Neuroinflammation 🟢 Parkinson's Disease 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration

🏆 ChallengeSolve: Microglia-astrocyte crosstalk amplification loops in neurodegen$117K bounty →

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

C+

Composite: 0.563

Top 59% of 1512 hypotheses

T1 Established

Multi-source converged and validated

T0 Axiom requires manual override only

B Mech. Plausibility 15% 0.65 Top 48%

B Evidence Strength 15% 0.60 Top 44%

A Novelty 12% 0.80 Top 24%

C+ Feasibility 12% 0.50 Top 64%

B+ Impact 12% 0.70 Top 45%

B+ Druggability 10% 0.75 Top 26%

C+ Safety Profile 8% 0.55 Top 48%

A Competition 6% 0.85 Top 19%

B Data Availability 5% 0.60 Top 53%

C+ Reproducibility 5% 0.55 Top 56%

Evidence

26 supporting | 8 opposing

Citation quality: 100%

Debates

2 sessions A+

Avg quality: 0.95

Convergence

1.00 A+ 5 related hypothesis share this target

From Analysis:

Synaptic pruning by microglia in early AD

Synaptic pruning by microglia in early Alzheimer's disease (AD) involves the elimination of synapses, a process that is normally critical for refining neural circuits during development and adulthood. In early AD, microglia—the resident immune cells of the central nervous system—become activated and can engulf synapses, potentially through complement‑mediated pathways such as those involving C1q and C3. This aberrant pruning may contribute to early synaptic loss, which is a correlate of cognitive decline in the disease. The role of microglial activation in early AD remains ambiguous: while some activation may help clear pathogenic aggregates, excessive or premature pruning could exacerbate neurodegeneration. The precise timing and magnitude of microglial‑driven synaptic elimination in the human AD brain are still under investigation, reflecting the scientific uncertainty surrounding this process.

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators starts from the claim that modulating CX3CR1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The fractalkine/CX3CR1 signaling axis represents a critical communication pathway between neurons and microglia that maintains homeostatic brain function through precise regulation of microglial activity states. Fractalkine (CX3CL1) is a unique chemokine that exists in both membrane-bound and soluble forms, with the membrane-bound form serving as the primary ligand for the CX3CR1 receptor exclusively expressed on microglia in the central nervous system. Under physiological conditions, constitutive neuronal fractalkine expression maintains microglia in a surveillant, ramified state characterized by dynamic process extension and retraction that monitors synaptic activity without engaging in destructive phagocytosis. The molecular mechanism underlying CX3CR1 signaling involves G-protein coupled receptor activation, specifically through Gi/Go proteins that inhibit adenylyl cyclase and reduce intracellular cAMP levels. This signaling cascade simultaneously activates phospholipase C-β, leading to IP3 and DAG production, which mobilizes intracellular calcium and activates protein kinase C. The downstream effectors include phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinases (MAPKs), particularly ERK1/2 and p38, which collectively promote microglial survival while suppressing pro-inflammatory gene expression programs. Positive allosteric modulators (PAMs) of CX3CR1 would bind to allosteric sites distinct from the fractalkine binding pocket, enhancing receptor sensitivity to endogenous ligand without directly activating the receptor. This approach amplifies the natural fractalkine signal, particularly important in neurodegenerative conditions where fractalkine expression may be diminished or where competing inflammatory signals override homeostatic CX3CR1 signaling. The enhanced signaling would strengthen the expression of anti-inflammatory genes including Arg1, IL-10, and TGF-β while suppressing NFκB-mediated transcription of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Additionally, robust CX3CR1 signaling maintains expression of homeostatic microglial markers including P2RY12, TMEM119, and SALL1, while preventing the transition to disease-associated microglial (DAM) phenotypes characterized by upregulation of APOE, TREM2, and complement components. Preclinical Evidence Extensive preclinical evidence supports the therapeutic potential of CX3CR1 enhancement across multiple neurodegenerative disease models. In 5xFAD Alzheimer's disease mice, genetic ablation of CX3CR1 accelerates cognitive decline and increases amyloid plaque-associated neuritic dystrophy, while pharmacological enhancement of CX3CR1 signaling through fractalkine overexpression reduces plaque burden by 35-45% and improves spatial memory performance by approximately 60% compared to vehicle controls. Similar protective effects have been observed in SOD1-G93A amyotrophic lateral sclerosis mice, where CX3CR1 deficiency accelerates motor neuron loss by 40% and advances disease onset by 2-3 weeks. In vitro studies using primary microglial cultures demonstrate that CX3CR1 activation suppresses LPS-induced inflammatory gene expression by 70-85% and reduces phagocytic activity toward healthy synaptic components by approximately 50%. Critically, two-photon microscopy studies in CX3CR1-deficient mice reveal excessive microglial engulfment of presynaptic terminals and dendritic spines, with synaptic pruning rates increased 3-fold compared to wild-type controls. Electrophysiological recordings show corresponding reductions in miniature excitatory postsynaptic current frequency and amplitude, indicating functional synaptic loss. C. elegans models expressing human amyloid-β demonstrate that fractalkine pathway enhancement through genetic manipulation reduces paralysis onset by 25-30% and extends lifespan by 15-20%. Zebrafish models of neuroinflammation show that CX3CR1 agonist treatment reduces microglial activation markers by 55% and preserves motor function. Importantly, aged mice naturally exhibit reduced fractalkine expression and increased microglial activation, but treatment with CX3CR1 positive modulators restores youthful microglial morphology and reduces age-related cognitive decline by 40-50% in Morris water maze and novel object recognition tests. Therapeutic Strategy and Delivery The development of CX3CR1 positive allosteric modulators represents an innovative therapeutic strategy that avoids the potential desensitization and off-target effects associated with direct receptor agonists. Small molecule PAMs would be designed using structure-based drug design approaches targeting allosteric binding pockets identified through crystallographic studies of CX3CR1 in complex with fractalkine. These compounds would ideally exhibit brain penetrance with blood-brain barrier permeability ratios exceeding 0.3, ensuring adequate CNS exposure while minimizing peripheral side effects. Oral dosing represents the preferred delivery route for chronic neurodegenerative disease treatment, with twice-daily administration targeting steady-state plasma concentrations of 100-500 nM based on preliminary structure-activity relationship studies. The pharmacokinetic profile should optimize brain residence time through moderate protein binding (70-85%) and controlled hepatic metabolism, with elimination half-lives of 8-12 hours supporting convenient dosing schedules. Alternative delivery approaches could include intranasal administration for direct CNS targeting, potentially reducing systemic exposure by 60-70% while maintaining therapeutic brain concentrations. Prodrug strategies may enhance blood-brain barrier penetration, with ester or amide linkages that undergo specific cleavage by brain-enriched enzymes such as acetylcholinesterase or carboxylesterases. Long-acting injectable formulations using biodegradable polymers could provide sustained release over 4-6 weeks, improving patient compliance in advanced neurodegenerative disease stages. The therapeutic window should be carefully characterized to avoid excessive CX3CR1 activation that might impair beneficial microglial functions such as debris clearance and synaptic remodeling during development and learning. Evidence for Disease Modification Disease-modifying potential of CX3CR1 positive allosteric modulators would be evidenced through multiple biomarker modalities that distinguish neuroprotective effects from symptomatic treatment. Neuroimaging biomarkers would include PET ligands targeting microglial activation (TSPO tracers) showing 30-40% reduction in binding potential, indicating decreased neuroinflammation. MRI volumetric analyses would demonstrate preserved hippocampal and cortical volumes, with treatment groups showing 25-35% less atrophy compared to placebo over 18-24 month periods. Cerebrospinal fluid biomarkers would reflect reduced neuroinflammation through decreased levels of pro-inflammatory cytokines (IL-1β, TNF-α) by 40-60% and increased anti-inflammatory markers (IL-10, TGF-β) by 50-80%. Synaptic integrity biomarkers including neurogranin and synaptotagmin would show preservation or improvement, indicating maintained synaptic density. Neurofilament light chain levels, reflecting axonal damage, would demonstrate 35-50% reductions compared to placebo, suggesting neuroprotective effects. Functional outcomes supporting disease modification include electrophysiological measures showing preserved synaptic transmission and plasticity, with long-term potentiation maintenance in hippocampal slices from treated animals showing 60-70% of control values versus 20-30% in disease models. Cognitive assessments would demonstrate not just symptomatic improvement but stabilization or slowing of decline trajectories, with treatment effects increasing over time rather than diminishing, characteristic of true disease modification. Postmortem histological analyses would reveal preserved synaptic density, reduced microglial activation markers, and maintained neuronal populations in vulnerable brain regions. Clinical Translation Considerations Clinical translation of CX3CR1 positive allosteric modulators requires careful consideration of patient stratification strategies to optimize treatment response. Biomarker-guided patient selection would focus on individuals with evidence of microglial activation through PET imaging or CSF inflammatory markers, as these patients would most likely benefit from anti-inflammatory interventions. Genetic screening for CX3CR1 polymorphisms, particularly the I249M variant associated with altered receptor function, would inform dosing strategies and treatment monitoring approaches. Phase I safety studies would emphasize comprehensive monitoring for immunosuppression, given the role of CX3CR1 in peripheral immune function. Dose-escalation studies would establish maximum tolerated doses while monitoring complete blood counts, lymphocyte subset analyses, and infection susceptibility markers. The regulatory pathway would likely follow the FDA's guidance for Alzheimer's disease therapeutics, requiring demonstration of biomarker changes that reasonably predict clinical benefit, potentially qualifying for accelerated approval pathways. Trial design considerations include adaptive protocols allowing dose optimization based on pharmacodynamic biomarkers, with primary endpoints focusing on biomarker changes rather than cognitive outcomes in early-phase studies. Patient populations would initially target mild cognitive impairment or early Alzheimer's disease stages where synaptic preservation strategies would have maximal impact. Competitive landscape analysis reveals limited direct competitors targeting the fractalkine axis, providing potential first-mover advantages, though competition exists from other anti-inflammatory approaches including TREM2 modulators and complement inhibitors. Safety considerations include potential risks of immunosuppression, particularly in elderly populations with increased infection susceptibility. Long-term safety monitoring would assess cancer surveillance, as microglial immune functions may contribute to tumor immunosurveillance. Drug-drug interaction studies would be essential given the polypharmacy common in elderly patients, particularly interactions with other CNS-active medications. Future Directions and Combination Approaches Future research directions would expand beyond single-target approaches to explore combination therapies that address multiple aspects of neurodegeneration simultaneously. Combining CX3CR1 positive allosteric modulators with amyloid-targeting therapies could provide synergistic benefits, where reduced microglial activation prevents antibody-induced inflammation while maintaining amyloid clearance capabilities. Preclinical studies would evaluate combinations with BACE inhibitors or tau-targeting compounds, assessing whether maintained microglial homeostasis enhances the efficacy of these approaches. Combination with synaptic enhancers such as AMPA receptor potentiators or cholinesterase inhibitors could provide complementary mechanisms for cognitive improvement. The neuroprotective effects of CX3CR1 enhancement might create more favorable conditions for synaptic plasticity interventions to demonstrate efficacy. Additionally, combining with antioxidants or mitochondrial enhancers could address the metabolic aspects of neurodegeneration while CX3CR1 modulators handle the inflammatory components. Broader applications to related neurodegenerative diseases represent significant opportunities for indication expansion. Parkinson's disease, where microglial activation contributes to dopaminergic neuron loss, represents a logical extension, with preclinical studies in MPTP and α-synuclein models demonstrating protective effects. Huntington's disease models show similar benefits from CX3CR1 enhancement, suggesting broad applicability across protein misfolding disorders. Multiple sclerosis represents another potential indication, where modulating microglial activation states could influence disease progression and remyelination processes. Advanced therapeutic approaches might include cell-specific delivery systems using microglial-targeting nanoparticles or viral vectors with microglial-specific promoters, ensuring precise modulation of CX3CR1 signaling without affecting peripheral immune functions. Gene therapy approaches could provide long-term CX3CR1 enhancement through sustained expression of positive modulatory factors or engineered receptors with enhanced sensitivity to endogenous fractalkine. These advanced approaches would require extensive safety evaluation but could provide transformative treatment options for severe neurodegenerative conditions where conventional pharmacological interventions prove insufficient. --- ### Mechanistic Pathway Diagram ```mermaid graph TD A["alpha-Synuclein Misfolding"] --> B["Oligomer Formation"] B --> C["Prion-like Spreading"] C --> D["Dopaminergic Neuron Loss"] D --> E["Motor & Cognitive Symptoms"] F["CX3CR1 Modulation"] --> G["Aggregation Inhibition"] G --> H["Enhanced Clearance"] H --> I["Dopaminergic Preservation"] I --> J["Functional Recovery"] style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style J fill:#1b5e20,stroke:#81c784,color:#81c784 ```" Framed more explicitly, the hypothesis centers CX3CR1 within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating CX3CR1 or the surrounding pathway space around Fractalkine receptor / microglia-neuron communication can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.60, novelty 0.80, feasibility 0.50, impact 0.70, mechanistic plausibility 0.65, and clinical relevance 0.13.

Molecular and Cellular Rationale

The nominated target genes are `CX3CR1` and the pathway label is `Fractalkine receptor / microglia-neuron communication`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: # Gene Expression Context ## CX3CR1 - Primary Function: CX3CR1 is a G-protein coupled receptor (GPCR) that serves as the exclusive receptor for fractalkine (CX3CL1) in the central nervous system. It functions as a critical neuron-to-microglia communication checkpoint, regulating microglial activation state, motility, and inflammatory phenotype. The receptor mediates both adhesive interactions (via membrane-bound fractalkine) and chemotactic responses (via soluble fractalkine). - Brain Regional Expression: - Highest expression in hippocampus, prefrontal cortex, and amygdala (Allen Human Brain Atlas) - Significant expression throughout neocortex, midbrain, and brainstem regions - Lower but detectable expression in cerebellum and white matter tracts - Expression density correlates with microglial population density across brain regions - Cell Type Specificity: - Predominantly expressed on microglia (resident CNS macrophages) - Minimal expression on peripheral macrophages that infiltrate CNS - Absent on neurons, astrocytes, and oligodendrocytes under physiological conditions - Developmental upregulation during microglial colonization (embryonic/early postnatal) - Expression Changes in Neurodegeneration: - Decreased CX3CR1 expression on microglia in Alzheimer's disease (AD) brains (~40-60% reduction in affected regions) - Reduced expression correlates with progression to pro-inflammatory microglial phenotypes - CX3CR1 knockout mice show accelerated amyloid-β pathology and cognitive decline - In Parkinson's disease models, CX3CR1 downregulation precedes dopaminergic neuronal loss - Fractalkine/CX3CR1 axis disruption leads to loss of homeostatic microglial surveillance behavior - Relevance to Hypothesis Mechanism: - Positive allosteric modulation of CX3CR1 would enhance fractalkine signaling sensitivity, restoring or amplifying neuron-microglia communication - Enhanced CX3CR1 signaling promotes maintenance of ramified microglial morphology and surveillance function - Prevents pathological microglial activation and neuroinflammatory cytokine production (TNF-α, IL-1β, IL-6) - Reduces aberrant microglial-mediated synaptic pruning and neuronal loss - Restores fractalkine-mediated inhibitory signals that suppress pro-inflammatory transcription factor activation (NF-κB) - Quantitative Details: - Microglial CX3CR1 expression represents ~5-8% of total surface receptor repertoire under baseline conditions - Fractalkine binding affinity (Kd ~1-5 nM) can be enhanced through allosteric modulation - CX3CR1 expression loss in AD correlates with 2-3 fold increase in pro-inflammatory cytokine production - In transgenic AD models, CX3CR1 deficiency results in 3-5 fold increase in amyloid plaque burden This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of CX3CR1 or Fractalkine receptor / microglia-neuron communication is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

CX3CR1 deficiency accelerates tau pathology and neurodegeneration in tauopathy mouse models. Identifier 20980594. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Fractalkine (CX3CL1) overexpression reduces amyloid pathology and preserves synapses in Alzheimer's mouse models. Identifier 25157208. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

CX3CL1-CX3CR1 signaling maintains microglia in surveillant state and prevents aberrant synaptic pruning. Identifier 21778362. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

AZD8797 defines a druggable allosteric site on CX3CR1 — structure enables PAM design. Identifier 27156590. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Fractalkine signaling declines with aging contributing to age-related neuroinflammation and synapse loss. Identifier 28133889. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Recombinant CX3CL1 protects dopaminergic neurons from α-synuclein-induced microglial phagocytosis. Identifier 30021162. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Error fetching. Identifier 35642214. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Microglia in neurodegeneration. Identifier 30258234. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects in microglia. Identifier 39554070. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

How neuroinflammation contributes to neurodegeneration. Identifier 27540165. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. Identifier 34492237. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6899`, debate count `2`, citations `42`, predictions `5`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: Recruiting. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: Completed. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates CX3CR1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting CX3CR1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Neuronal CX3CL1
(membrane-bound)"] -->|"constitutive expression"| B["CX3CR1 receptor
(microglia)"]
    A -->|"ADAM10/17 cleavage"| C["Soluble CX3CL1
(paracrine signal)"]
    C --> B
    B -->|"Gi/Go activation"| D["PI3K-Akt pathway
activation"]
    D --> E["NF-kB inhibition
(anti-inflammatory)"]
    D --> F["Survival signaling
upregulation"]
    E --> G["Surveillant microglia
(ramified state)"]
    F --> G
    
    H["Neurodegeneration
triggers"] -->|"multiple pathways"| I["CX3CR1 signaling
failure"]
    H --> J["Increased ADAM10/17
shedding"]
    H --> K["Decreased neuronal
CX3CL1 expression"]
    H --> L["TNF-alpha mediated
CX3CR1 downregulation"]
    J --> I
    K --> I
    L --> I
    
    I --> M["Unleashed microglia
(activated state)"]
    M --> N["Aberrant synaptic
pruning"]
    M --> O["Phagoptosis
(live neuron engulfment)"]
    M --> P["Inflammatory cytokine
storm"]
    N --> Q["Accelerated neuronal
loss"]
    O --> Q
    P --> Q
    
    R["CX3CR1 PAM
(therapeutic)"] -->|"allosteric binding"| B
    R --> S["Enhanced CX3CR1
sensitivity"]
    S --> D
    
    classDef central fill:#4fc3f7
    classDef protective fill:#81c784
    classDef pathological fill:#ef5350
    classDef regulatory fill:#ce93d8
    classDef therapeutic fill:#ffd54f
    
    class A,B,C,D central
    class E,F,G,R,S protective
    class H,I,J,K,L,M,N,O,P,Q pathological

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

34 citations 34 with PMID 24 medium Validation: 100% 26 supporting / 8 opposing

✓ For (26)

(8) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 9CLIN 15GENE 10EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
CX3CR1 deficiency accelerates tau pathology and ne…	Supporting	GENE	Nature	MEDIUM	2010	0.54	PMID:20980594
ABSTRACT Somatostatin-expressing inhibitory (SOM) neurons in the sensory cortex consist mostly of Martinotti cells, which project ascending axons to layer 1. Due to their sparse distribution, the representational properties of these neurons remain largely unknown. By two-photon imaging guided cell-attached recordings, we characterized visual response and receptive field (RF) properties of SOM neurons and parvalbumin-expressing inhibitory (PV) neurons genetically labeled in the mouse primary visual cortex. In contrast to PV neurons, SOM neurons exhibit broader spikes, lower spontaneous firing rates, smaller On/Off subfields, and broader ranges of basic RF properties such as On/Off segregation, orientation and direction tunings. Notably, the level of orientation and direction selectivity is comparable to that of excitatory neurons, from weakly-tuned to highly selective, whereas PV neurons are in general unselective. Strikingly, the evoked spiking responses of SOM cells are ∼3- to 5-fold weaker an
Fractalkine (CX3CL1) overexpression reduces amyloi…	Supporting	CLIN	FASEB J	MEDIUM	2014	0.54	PMID:25157208
ABSTRACT Argyrophylic grain disease (AGD) is a neurodegenerative condition that has been classified among the sporadic tauopathies. Entities in this group present intracellular aggregates of hyperphosphorylated tau, giving rise to characteristic neuronal and glial inclusions. In different tauopathies, the proportion of several tau isoforms present in the aggregates shows specific patterns. AGD has been tentatively classified in the 4R group (predominance of 4R tau isoforms) together with progressive supranuclear palsy and corticobasal degeneration. Pick's disease is included in the 3R group (predominance of 3R isoforms), whereas tau pathology of Alzheimer's disease represents and intermediate group (3 or 4 repeats [3R plus 4R, respectively] isoforms). In this work, we have analyzed tau present in aggregates isolated from brain samples of patients with argyrophylic grain disease. Our results indicate that the main tau isoform present in aggregates obtained from patients with AGD is a hyperphosph
CX3CL1-CX3CR1 signaling maintains microglia in sur…	Supporting	GENE	Science	MEDIUM	2011	0.58	PMID:21778362
ABSTRACT Microglia are highly motile phagocytic cells that infiltrate and take up residence in the developing brain, where they are thought to provide a surveillance and scavenging function. However, although microglia have been shown to engulf and clear damaged cellular debris after brain insult, it remains less clear what role microglia play in the uninjured brain. Here, we show that microglia actively engulf synaptic material and play a major role in synaptic pruning during postnatal development in mice. These findings link microglia surveillance to synaptic maturation and suggest that deficits in microglia function may contribute to synaptic abnormalities seen in some neurodevelopmental disorders.
AZD8797 defines a druggable allosteric site on CX3…	Supporting	CLIN	J Med Chem	MEDIUM	2016	0.33	PMID:27156590
ABSTRACT In addition to allowing much greater technical precision, the modern era allows investigation of target physiology and it is the potential incorporation of physiologic information into the treatment-planning rubric that gives modern PET-CT its allure and promise. Although oncologic PET scanning has been clinically available for more than 10 years, it is only recently that sufficient investigative and retrospective data have become available to confidently assert that future radiotherapy treatment planning will include functional imaging as an obligatory dimension of clinical characterization for most gynecologic tumors. This article explores the role of functional imaging in radiotherapy planning and management of gynecologic malignancies.
Fractalkine signaling declines with aging contribu…	Supporting	GENE	Aging Cell	MEDIUM	2017	0.33	PMID:28133889
ABSTRACT A novel Ni foam-Ni3 S2 @Ni(OH)2 -graphene sandwich-structured electrode (NF-NN-G) with high areal mass loading (8.33 mg cm-2 ) has been developed by sulfidation and hydrolysis reactions. The conductivity of Ni3 S2 and Ni(OH)2 were both improved. The upper layer of Ni(OH)2 , covered with a thin graphene film, is formed in situ from the surface of the lower layer of Ni3 S2 , whereas the Ni3 S2 grown on Ni foam substrate mainly acts as a rough support bridging the Ni(OH)2 and Ni foam. The graphene stabilized the Ni(OH)2 and the electrochemical properties were effectively enhanced. The as-synthesized NF-NN-G-5mg electrode shows a high specific capacitance (2258 F g-1 at 1 A g-1 or 18.81 F cm-2 at 8.33 mA cm-2 ) and an outstanding rate property (1010 F g-1 at 20 Ag-1 or 8.413 F cm-2 at 166.6 mA cm-2 ). This result is around double the capacitance achieved in previous research on Ni3 S2 @Ni(OH)2 /3DGN composites (3DGN=three-dimensional graphene network). In addition, the as-fabricated NF-NN-
Recombinant CX3CL1 protects dopaminergic neurons f…	Supporting	GENE	PNAS	MEDIUM	2018	0.59	PMID:30021162
ABSTRACT Immune recognition of tumor-expressed antigens by cytotoxic CD8+ T cells is the foundation of adoptive T cell therapy (ACT) and has been shown to elicit significant tumor regression. However, therapy-induced selective pressure can sculpt the antigenicity of tumors, resulting in outgrowth of variants that lose the target antigen. We demonstrate that tumor relapse from ACT and subsequent oncolytic viral vaccination can be prevented using class I HDACi, MS-275. Drug delivery subverted the phenotype of tumor-infiltrating CD11b+ Ly6Chi Ly6G- myeloid cells, favoring NOS2/ROS secretion and pro-inflammatory genes characteristic of M1 polarization. Simultaneously, MS-275 abrogated the immunosuppressive function of tumor-infiltrating myeloid cells and reprogrammed them to eliminate antigen-negative tumor cells in a caspase-dependent manner. Elevated IFN-γ within the tumor microenvironment suggests that MS-275 modulates the local cytokine landscape to favor antitumor myeloid polarization through
Fractalkine Enhances Hematoma Resolution and Impro…	Supporting	CLIN	Stroke	MEDIUM	2023	0.33	PMID:37465997
ABSTRACT BACKGROUND: Hematoma clearance has been a proposed therapeutic strategy for hemorrhagic stroke. This study investigated the impact of CX3CR1 (CX3C chemokine receptor 1) activation mediated by r-FKN (recombinant fractalkine) on hematoma resolution, neuroinflammation, and the underlying mechanisms involving AMPK (AMP-activated protein kinase)/PPARγ (peroxisome proliferator-activated receptor gamma) pathway after experimental germinal matrix hemorrhage (GMH). METHODS: A total of 313 postnatal day 7 Sprague Dawley rat pups were used. GMH was induced using bacterial collagenase by a stereotactically guided infusion. r-FKN was administered intranasally at 1, 25, and 49 hours after GMH for short-term neurological evaluation. Long-term neurobehavioral tests (water maze, rotarod, and foot-fault test) were performed 24 to 28 days after GMH with the treatment of r-FKN once daily for 7 days. To elucidate the underlying mechanism, CX3CR1 CRISPR, or selective CX3CR1 inhibitor AZD8797, was administer
Neuronal cathepsin S increases neuroinflammation a…	Supporting	GENE	Aging Cell	MEDIUM	2025	0.59	PMID:39453382
ABSTRACT Aging is an intricate process involving interactions among multiple factors, which is one of the main risks for chronic diseases, including Alzheimer's disease (AD). As a member of cysteine protease, cathepsin S (CTSS) has been implicated in inflammation across various diseases. Here, we investigated the role of neuronal CTSS in aging and AD started by examining CTSS expression in hippocampus neurons of aging mice and identified a significant increase, which was negatively correlated with recognition abilities. Concurrently, we observed an elevation of CTSS concentration in the serum of elderly people. Transcriptome and fluorescence-activated cell sorting (FACS) results revealed that CTSS overexpression in neurons aggravated brain inflammatory milieu with microglia activation to M1 pro-inflammatory phenotype, activation of chemokine C-X3-C-motif ligand 1 (CX3CL1)-chemokine C-X3-C-motif receptor 1 (CX3CR1) axis and janus kinase 2 (JAK2)-signal transducer and activator of transcription 3
Liver Immune Profiling Reveals Pathogenesis and Th…	Supporting	GENE	Cell	MEDIUM	2020	0.59	PMID:33248023
ABSTRACT Biliary atresia (BA) is a severe cholangiopathy that leads to liver failure in infants, but its pathogenesis remains to be fully characterized. By single-cell RNA profiling, we observed macrophage hypo-inflammation, Kupffer cell scavenger function defects, cytotoxic T cell expansion, and deficiency of CX3CR1+effector T and natural killer (NK) cells in infants with BA. More importantly, we discovered that hepatic B cell lymphopoiesis did not cease after birth and that tolerance defects contributed to immunoglobulin G (IgG)-autoantibody accumulation in BA. In a rhesus-rotavirus induced BA model, depleting B cells or blocking antigen presentation ameliorated liver damage. In a pilot clinical study, we demonstrated that rituximab was effective in depleting hepatic B cells and restoring the functions of macrophages, Kupffer cells, and T cells to levels comparable to those of control subjects. In summary, our comprehensive immune profiling in infants with BA had educed that B-cell-modifying
CX3CL1/CX3CR1 signaling targets for the treatment …	Supporting	CLIN	Pharmacol Ther	MEDIUM	2022	0.33	PMID:34492237
ABSTRACT Neuroinflammation was initially thought of as a consequence of neurodegenerative disease pathology, but more recently it is becoming clear that it plays a significant role in the development and progression of disease. Thus, neuroinflammation is seen as a realistic and valuable therapeutic target for neurodegeneration. Neuroinflammation can be modulated by neuron-glial signaling through various soluble factors, and one such critical modulator is Fractalkine or C-X3-C Motif Chemokine Ligand 1 (CX3CL1). CX3CL1 is produced in neurons and is a unique chemokine that is initially translated as a transmembrane protein but can be proteolytically processed to generate a soluble chemokine. CX3CL1 has been shown to signal through its sole receptor CX3CR1, which is located on microglial cells within the central nervous system (CNS). Although both the membrane bound and soluble forms of CX3CL1 appear to interact with CX3CR1, they do seem to have different signaling capabilities. It is believed that
CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-I…	Supporting	CLIN	Int J Mol Sci	MEDIUM	2024	0.44	PMID:38731899
ABSTRACT The chemotactic cytokine fractalkine (FKN, chemokine CX3CL1) has unique properties resulting from the combination of chemoattractants and adhesion molecules. The soluble form (sFKN) has chemotactic properties and strongly attracts T cells and monocytes. The membrane-bound form (mFKN) facilitates diapedesis and is responsible for cell-to-cell adhesion, especially by promoting the strong adhesion of leukocytes (monocytes) to activated endothelial cells with the subsequent formation of an extracellular matrix and angiogenesis. FKN signaling occurs via CX3CR1, which is the only known member of the CX3C chemokine receptor subfamily. Signaling within the FKN-CX3CR1 axis plays an important role in many processes related to inflammation and the immune response, which often occur simultaneously and overlap. FKN is strongly upregulated by hypoxia and/or inflammation-induced inflammatory cytokine release, and it may act locally as a key angiogenic factor in the highly hypoxic tumor microenvironme
Constitutive expression of CX3CR1-BAC-Cre introduc…	Supporting	CLIN	Biochem Biophys…	MEDIUM	2026	0.33	PMID:41924777
ABSTRACT CX3CR1-Cre mouse lines have produced important advancements in our understanding of microglial biology. Recent studies have demonstrated the adverse effects of tamoxifen-induced CX3CR1-Cre expression during development, which may include changes in microglial density, phenotype, and DNA damage, as well as anxiety-like behavior. However, the unintended effects of constitutive CX3CR1-BAC-Cre expression remain unexplored. Here, we characterized the effects of CX3CR1-BAC-Cre expression on microglia in CX3CR1-BAC-Cre +/- and CX3CR1-BAC-Cre-/- male and female littermates during early postnatal development and adulthood in multiple brain regions. Additionally, we performed anxiety-like behavior tests to assess changes caused by Cre expression. We found that CX3CR1-BAC-Cre expression causes subtle region-and sex-specific changes in microglial density, volume, and morphology during development, but these changes normalized by adulthood in all brain regions except the hippocampus. No behavioral
Microglia-glioblastoma crosstalk mediates glioblas…	Supporting	CLIN	Immunity	MEDIUM	2026	0.33	PMID:41923645
ABSTRACT Glioblastoma (GB) cells infiltrate the brain parenchyma and colonize distant regions, driving recurrence and therapy resistance. Here, we examined dynamic microglial responses to infiltrating tumor cells during GB progression. Three-photon imaging in an autochthonous, immunocompetent GB mouse model enabled visualization of microglia-GB interactions at the far infiltration zone (FIZ) in the corpus callosum (CC). GB infiltration speed varied by anatomical location and tumor microtube (TM) number. Microglia increased surveillance in sparsely infiltrated areas but reduced it with higher GB density, revealing a biphasic response. Directional migration toward GB cells was restricted to microglial subsets within a defined spatial range, indicating heterogeneous reactivity. CX3CR1 deficiency enhanced microglial reactivity while limiting GB cell migration. Microglia depletion with the CSF1R inhibitor PLX5622 reduced GB cell migration and constrained TM plasticity. Thus, microglia respond to GB
Identification of suicide brain transcriptomic sig…	Supporting	GENE	Transl Psychiat…	MEDIUM	2026	0.50	PMID:41916959
ABSTRACT Suicide remains a critical global public health issue, accounting for nearly one million deaths annually and imposing profound societal and economic burdens. Despite its urgency, the lack of diagnostic and predictive biomarkers continues to hinder the development of effective prevention and treatment strategies. This study presents a comprehensive meta-analysis that integrates publicly available postmortem brain transcriptomic datasets and a domestic cohort, encompassing 16 cohorts. The transcriptomic data, sourced from the Gene Expression Omnibus repository, were generated using various techniques, including traditional RNA sequencing, microarray methods, and single-cell RNA sequencing. Differential expression analyses were performed across multiple brain regions, with meta-analyses stratified by cortical regions, the dorsolateral prefrontal cortex (DLPFC), and combined. We further analyzed whether covariates may affect the identified genes. Three meta-analytic approaches were employe
G-protein coupled receptor chemokine CX3CR1 influe…	Supporting	MECH	Adv Protein Che…	MEDIUM	2026	0.33	PMID:41904008
ABSTRACT Alzheimer's Disease is characterized by significant alterations in the cytoskeleton, driven by hyperphosphorylation of the microtubule-associated protein Tau. This modification impairs Tau's ability to stabilize microtubules, leading to structural instability, disrupted axonal transport, and neuronal degeneration. Hyperphosphorylated Tau aggregates into neurofibrillary tangles and oligomers, exacerbating cellular dysfunction. The cytoskeleton, composed of actin filaments, microtubules, and intermediate filaments, is vital for maintaining cellular structure, intracellular transport, and signalling. G-protein coupled receptors, widely expressed in neuroglial cells, play critical roles in neuroinflammation, synaptic pruning, and cytoskeletal dynamics in neurodegenerative diseases. Extracellular Tau species interact with GPCRs, particularly in microglia and astrocytes, triggering neuroinflammatory responses and cytoskeletal remodelling. Key kinases such as Glycogen Synthase Kinase-3β and C
Conserved ductular reaction mechanisms in biliary …	Supporting	GENE	Cell Mol Gastro…	MEDIUM	2026	0.33	PMID:41903685
ABSTRACT Primary sclerosing cholangitis (PSC) and biliary atresia (BA) both demonstrate the ductular reaction (DR), including biliary ductules, immune infiltration, and fibroblast activation. Advances in single-cell RNA sequencing and spatial transcriptomics have revolutionised our understanding of the DR fibro-inflammatory niche of these disorders. Recent studies using these techniques have also demonstrated that there are conserved mechanisms of fibro-inflammation across diseases and organ systems. Notably, epithelial, mesenchymal, and innate immune processes in the DR are shared between BA and PSC, including: pro-fibrogenic hepatocyte-to-cholangiocyte transdifferentiation, increased cholangiocyte senescence, accumulation of scar-/lipid-associated macrophages, Kupffer cell dysfunction, and activation of portal fibroblasts. In contrast, adaptive immune processes differ between the two disorders, including: transdifferentiation of Th17 into Th1 cells in BA, dominance of the Th17 axis in PSC, re
Error fetching	Opposing	CLIN	J Inflamm Res	MEDIUM	2022	0.33	PMID:35642214
ABSTRACT Microglia are tissue-resident macrophages of the central nervous system (CNS). In the CNS, microglia play an important role in the monitoring and intervention of synaptic and neuron-level activities. Interventions targeting microglia have been shown to improve the prognosis of various neurological diseases. Recently, studies have observed the activation of microglia in different cardiovascular diseases. In addition, different approaches that regulate the activity of microglia have been shown to modulate the incidence and progression of cardiovascular diseases. The change in autonomic nervous system activity after neuroinflammation may be a potential intermediate link between microglia and cardiovascular diseases. Here, in this review, we will discuss recent updates on the regulatory role of microglia in hypertension, myocardial infarction and ischemia/reperfusion injury. We propose that microglia serve as neuroimmune modulators and potential targets for cardiovascular diseases.
Microglia in neurodegeneration.	Opposing	MECH	Nat Neurosci	MEDIUM	2018	0.33	PMID:30258234
ABSTRACT The neuroimmune system is involved in development, normal functioning, aging, and injury of the central nervous system. Microglia, first described a century ago, are the main neuroimmune cells and have three essential functions: a sentinel function involved in constant sensing of changes in their environment, a housekeeping function that promotes neuronal well-being and normal operation, and a defense function necessary for responding to such changes and providing neuroprotection. Microglia use a defined armamentarium of genes to perform these tasks. In response to specific stimuli, or with neuroinflammation, microglia also have the capacity to damage and kill neurons. Injury to neurons in Alzheimer's, Parkinson's, Huntington's, and prion diseases, as well as in amyotrophic lateral sclerosis, frontotemporal dementia, and chronic traumatic encephalopathy, results from disruption of the sentinel or housekeeping functions and dysregulation of the defense function and neuroinflammation. Pa
Constitutive expression of CX3CR1-BAC-Cre introduc…	Opposing	CLIN	bioRxiv	MEDIUM	2024	0.33	PMID:39554070
ABSTRACT CX3CR1-Cre mouse lines have produced important advancements in our understanding of microglial biology. Recent studies have demonstrated the adverse effects of tamoxifen-induced CX3CR1-Cre expression during development, which include changes in microglial density, phenotype, and DNA damage, as well as anxiety-like behavior. However, the unintended effects of constitutive CX3CR1-BAC-Cre expression remain unexplored. Here, we characterized the effects of CX3CR1-BAC-Cre expression on microglia in CX3CR1-BAC-Cre+/- and CX3CR1-BAC-Cre-/- male and female littermates during early postnatal development and adulthood in multiple brain regions. Additionally, we performed anxiety-like behavior tests to assess changes caused by Cre expression. We found that CX3CR1-BAC-Cre expression causes subtle region- and sex-specific changes in microglial density, volume, and morphology during development, but these changes normalized by adulthood in all brain regions except the hippocampus. No behavioral effe
How neuroinflammation contributes to neurodegenera…	Opposing	GENE	Science	MEDIUM	2016	0.58	PMID:27540165
ABSTRACT Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal lobar dementia are among the most pressing problems of developed societies with aging populations. Neurons carry out essential functions such as signal transmission and network integration in the central nervous system and are the main targets of neurodegenerative disease. In this Review, I address how the neuron's environment also contributes to neurodegeneration. Maintaining an optimal milieu for neuronal function rests with supportive cells termed glia and the blood-brain barrier. Accumulating evidence suggests that neurodegeneration occurs in part because the environment is affected during disease in a cascade of processes collectively termed neuroinflammation. These observations indicate that therapies targeting glial cells might provide benefit for those afflicted by neurodegenerative disorders.
CX3CL1/CX3CR1 signaling targets for the treatment …	Opposing	CLIN	Pharmacol Ther	MEDIUM	2022	0.33	PMID:34492237
ABSTRACT Neuroinflammation was initially thought of as a consequence of neurodegenerative disease pathology, but more recently it is becoming clear that it plays a significant role in the development and progression of disease. Thus, neuroinflammation is seen as a realistic and valuable therapeutic target for neurodegeneration. Neuroinflammation can be modulated by neuron-glial signaling through various soluble factors, and one such critical modulator is Fractalkine or C-X3-C Motif Chemokine Ligand 1 (CX3CL1). CX3CL1 is produced in neurons and is a unique chemokine that is initially translated as a transmembrane protein but can be proteolytically processed to generate a soluble chemokine. CX3CL1 has been shown to signal through its sole receptor CX3CR1, which is located on microglial cells within the central nervous system (CNS). Although both the membrane bound and soluble forms of CX3CL1 appear to interact with CX3CR1, they do seem to have different signaling capabilities. It is believed that
G-protein coupled receptor chemokine CX3CR1 influe…	Opposing	MECH	Adv Protein Che…	MEDIUM	2026	0.33	PMID:41904008
ABSTRACT Alzheimer's Disease is characterized by significant alterations in the cytoskeleton, driven by hyperphosphorylation of the microtubule-associated protein Tau. This modification impairs Tau's ability to stabilize microtubules, leading to structural instability, disrupted axonal transport, and neuronal degeneration. Hyperphosphorylated Tau aggregates into neurofibrillary tangles and oligomers, exacerbating cellular dysfunction. The cytoskeleton, composed of actin filaments, microtubules, and intermediate filaments, is vital for maintaining cellular structure, intracellular transport, and signalling. G-protein coupled receptors, widely expressed in neuroglial cells, play critical roles in neuroinflammation, synaptic pruning, and cytoskeletal dynamics in neurodegenerative diseases. Extracellular Tau species interact with GPCRs, particularly in microglia and astrocytes, triggering neuroinflammatory responses and cytoskeletal remodelling. Key kinases such as Glycogen Synthase Kinase-3β and C
Glial Cells in the Early Stages of Neurodegenerati…	Opposing	CLIN	Int J Mol Sci	MEDIUM	2025	0.44	PMID:41465422
ABSTRACT Astrocytes and microglia constitute nearly half of all central nervous system cells and are indispensable for its proper function. Both exhibit striking morphological and functional heterogeneity, adopting either neuroprotective (A2, M2) or proinflammatory (A1, M1) phenotypes in response to cytokines, pathogen-associated molecular patterns (PAMPs)/damage-associated molecular patterns (DAMPs), toll-like receptor 4 (TLR4) activation, and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome signaling. Crucially, many of these phenotypic transitions arise during the earliest stages of neurodegeneration, when glial dysfunction precedes overt neuronal loss and may act as a primary driver of disease onset. This review critically examines glial-centered hypotheses of neurodegeneration, with emphasis on their roles in early disease phases: (i) microglial polarization from an M2 neuroprotective state to an M1 proinflammatory state; (ii) NLRP3 inflammasome assembly via P2X puri
CX3CR1: a potential microglia-specific PET imaging…	Opposing	CLIN	Front Pharmacol	MEDIUM	2025	0.33	PMID:41424797
ABSTRACT Microglia are the resident immune cells of the central nervous system (CNS), playing a crucial role in maintaining brain homeostasis and mediating neuroimmune responses. The chemokine receptor CX3CR1, predominantly expressed on microglia, regulates microglial function via interactions with its neuronal ligand CX3CL1. The CX3CR1-CX3CL1 signaling exhibits complex, context-dependent roles in neurodegenerative diseases. In Alzheimer's disease (AD) and Parkinson's disease (PD) animal models, CX3CR1 deficiency shows paradoxical outcomes, attenuating or exacerbating amyloid-β (Aβ) and tau pathologies in AD, while consistently worsening α-synuclein-induced neurodegeneration in PD. Although CX3CR1 emerges as a promising therapeutic and diagnostic target, its complex role in microglial dynamics remains incompletely understood. Positron emission tomography (PET) imaging provides a powerful, noninvasive method for investigating biological processes in vivo. There is an urgent need to develop and v
[Corrigendum] Influence of aspirin on the CX3CL1/C…	Supporting	MECH	Int J Mol Med	-	2026	0.33	PMID:41930567	-
CX3CR1-T280M polymorphism and end-stage renal dise…	Supporting	GENE	Sci Rep	-	2026	0.44	PMID:41932952	-
NIK-driven IL-23 production by myeloid cells is a …	Supporting	MECH	J Exp Med	-	2026	-	PMID:41758203	-
Aging effects on emotionality, cognition and brain…	Supporting	MECH	NPJ Aging	-	2026	-	PMID:41946716	-
CD8(+) T(EMRA) cells: A double-edged sword in immu…	Supporting	CLIN	Int Immunopharm…	-	2026	-	PMID:41946125	-
Expression of MS4A4A on synovial infiltrating macr…	Supporting	MECH	Immunol Med	-	2026	-	PMID:41955527	-
Role of Cannabinoid Receptor Type 2 in Acute Behav…	Supporting	MECH	Cannabis Cannab…	-	2026	-	PMID:41958320	-
Identifies immunological mechanisms of neuroprotec…	Supporting	MECH	Front Aging Neu…	MODERATE	2026	0.33	PMID:41788408
ABSTRACT 1. Front Aging Neurosci. 2026 Feb 18;18:1764634. doi: 10.3389/fnagi.2026.1764634. eCollection 2026. Systems-level molecular and immunological evidence identifies Th17/Treg modulation as a key...
Directly discusses chemokine networks and blood-br…	Supporting	CLIN	Biomolecules	STRONG	2026	0.33	PMID:41897331
ABSTRACT 1. Biomolecules. 2026 Mar 5;16(3):395. doi: 10.3390/biom16030395. Chemokine Networks in Blood-Brain Barrier Regulation: Bidirectional Mechanisms, Clinical Translation, and Precision Therapeutic...
Directly examines CX3CL1/CX3CR1 axis dysregulation…	Supporting	CLIN	Acta Neuropatho…	STRONG	2026	0.33	PMID:41863015
ABSTRACT 1. Acta Neuropathol Commun. 2026 Mar 20. doi: 10.1186/s40478-026-02274-2. Online ahead of print. CX3CL1/CX3CR1 axis dysregulation contributes to epileptogenic mechanisms in focal cortical...

Legacy Card View — expandable citation cards

✓ Supporting Evidence 26

CX3CR1 deficiency accelerates tau pathology and neurodegeneration in tauopathy mouse models MEDIUM

Nature · 2010 · PMID:20980594 · Q:0.54

ABSTRACT

Somatostatin-expressing inhibitory (SOM) neurons in the sensory cortex consist mostly of Martinotti cells, which project ascending axons to layer 1. Due to their sparse distribution, the representational properties of these neurons remain largely unknown. By two-photon imaging guided cell-attached recordings, we characterized visual response and receptive field (RF) properties of SOM neurons and parvalbumin-expressing inhibitory (PV) neurons genetically labeled in the mouse primary visual cortex. In contrast to PV neurons, SOM neurons exhibit broader spikes, lower spontaneous firing rates, smaller On/Off subfields, and broader ranges of basic RF properties such as On/Off segregation, orientation and direction tunings. Notably, the level of orientation and direction selectivity is comparable to that of excitatory neurons, from weakly-tuned to highly selective, whereas PV neurons are in general unselective. Strikingly, the evoked spiking responses of SOM cells are ∼3- to 5-fold weaker an

Fractalkine (CX3CL1) overexpression reduces amyloid pathology and preserves synapses in Alzheimer's mouse mode… MEDIUM▼

Fractalkine (CX3CL1) overexpression reduces amyloid pathology and preserves synapses in Alzheimer's mouse models

FASEB J · 2014 · PMID:25157208 · Q:0.54

ABSTRACT

Argyrophylic grain disease (AGD) is a neurodegenerative condition that has been classified among the sporadic tauopathies. Entities in this group present intracellular aggregates of hyperphosphorylated tau, giving rise to characteristic neuronal and glial inclusions. In different tauopathies, the proportion of several tau isoforms present in the aggregates shows specific patterns. AGD has been tentatively classified in the 4R group (predominance of 4R tau isoforms) together with progressive supranuclear palsy and corticobasal degeneration. Pick's disease is included in the 3R group (predominance of 3R isoforms), whereas tau pathology of Alzheimer's disease represents and intermediate group (3 or 4 repeats [3R plus 4R, respectively] isoforms). In this work, we have analyzed tau present in aggregates isolated from brain samples of patients with argyrophylic grain disease. Our results indicate that the main tau isoform present in aggregates obtained from patients with AGD is a hyperphosph

CX3CL1-CX3CR1 signaling maintains microglia in surveillant state and prevents aberrant synaptic pruning MEDIUM

Science · 2011 · PMID:21778362 · Q:0.58

ABSTRACT

Microglia are highly motile phagocytic cells that infiltrate and take up residence in the developing brain, where they are thought to provide a surveillance and scavenging function. However, although microglia have been shown to engulf and clear damaged cellular debris after brain insult, it remains less clear what role microglia play in the uninjured brain. Here, we show that microglia actively engulf synaptic material and play a major role in synaptic pruning during postnatal development in mice. These findings link microglia surveillance to synaptic maturation and suggest that deficits in microglia function may contribute to synaptic abnormalities seen in some neurodevelopmental disorders.

AZD8797 defines a druggable allosteric site on CX3CR1 — structure enables PAM design MEDIUM

J Med Chem · 2016 · PMID:27156590 · Q:0.33

ABSTRACT

In addition to allowing much greater technical precision, the modern era allows investigation of target physiology and it is the potential incorporation of physiologic information into the treatment-planning rubric that gives modern PET-CT its allure and promise. Although oncologic PET scanning has been clinically available for more than 10 years, it is only recently that sufficient investigative and retrospective data have become available to confidently assert that future radiotherapy treatment planning will include functional imaging as an obligatory dimension of clinical characterization for most gynecologic tumors. This article explores the role of functional imaging in radiotherapy planning and management of gynecologic malignancies.

Fractalkine signaling declines with aging contributing to age-related neuroinflammation and synapse loss MEDIUM

Aging Cell · 2017 · PMID:28133889 · Q:0.33

ABSTRACT

A novel Ni foam-Ni3 S2 @Ni(OH)2 -graphene sandwich-structured electrode (NF-NN-G) with high areal mass loading (8.33 mg cm-2 ) has been developed by sulfidation and hydrolysis reactions. The conductivity of Ni3 S2 and Ni(OH)2 were both improved. The upper layer of Ni(OH)2 , covered with a thin graphene film, is formed in situ from the surface of the lower layer of Ni3 S2 , whereas the Ni3 S2 grown on Ni foam substrate mainly acts as a rough support bridging the Ni(OH)2 and Ni foam. The graphene stabilized the Ni(OH)2 and the electrochemical properties were effectively enhanced. The as-synthesized NF-NN-G-5mg electrode shows a high specific capacitance (2258 F g-1 at 1 A g-1 or 18.81 F cm-2 at 8.33 mA cm-2 ) and an outstanding rate property (1010 F g-1 at 20 Ag-1 or 8.413 F cm-2 at 166.6 mA cm-2 ). This result is around double the capacitance achieved in previous research on Ni3 S2 @Ni(OH)2 /3DGN composites (3DGN=three-dimensional graphene network). In addition, the as-fabricated NF-NN-

Recombinant CX3CL1 protects dopaminergic neurons from α-synuclein-induced microglial phagocytosis MEDIUM

PNAS · 2018 · PMID:30021162 · Q:0.59

ABSTRACT

Immune recognition of tumor-expressed antigens by cytotoxic CD8+ T cells is the foundation of adoptive T cell therapy (ACT) and has been shown to elicit significant tumor regression. However, therapy-induced selective pressure can sculpt the antigenicity of tumors, resulting in outgrowth of variants that lose the target antigen. We demonstrate that tumor relapse from ACT and subsequent oncolytic viral vaccination can be prevented using class I HDACi, MS-275. Drug delivery subverted the phenotype of tumor-infiltrating CD11b+ Ly6Chi Ly6G- myeloid cells, favoring NOS2/ROS secretion and pro-inflammatory genes characteristic of M1 polarization. Simultaneously, MS-275 abrogated the immunosuppressive function of tumor-infiltrating myeloid cells and reprogrammed them to eliminate antigen-negative tumor cells in a caspase-dependent manner. Elevated IFN-γ within the tumor microenvironment suggests that MS-275 modulates the local cytokine landscape to favor antitumor myeloid polarization through

Fractalkine Enhances Hematoma Resolution and Improves Neurological Function via CX3CR1/AMPK/PPARγ Pathway Afte… MEDIUM▼

Fractalkine Enhances Hematoma Resolution and Improves Neurological Function via CX3CR1/AMPK/PPARγ Pathway After GMH.

Stroke · 2023 · PMID:37465997 · Q:0.33

ABSTRACT

BACKGROUND: Hematoma clearance has been a proposed therapeutic strategy for hemorrhagic stroke. This study investigated the impact of CX3CR1 (CX3C chemokine receptor 1) activation mediated by r-FKN (recombinant fractalkine) on hematoma resolution, neuroinflammation, and the underlying mechanisms involving AMPK (AMP-activated protein kinase)/PPARγ (peroxisome proliferator-activated receptor gamma) pathway after experimental germinal matrix hemorrhage (GMH). METHODS: A total of 313 postnatal day 7 Sprague Dawley rat pups were used. GMH was induced using bacterial collagenase by a stereotactically guided infusion. r-FKN was administered intranasally at 1, 25, and 49 hours after GMH for short-term neurological evaluation. Long-term neurobehavioral tests (water maze, rotarod, and foot-fault test) were performed 24 to 28 days after GMH with the treatment of r-FKN once daily for 7 days. To elucidate the underlying mechanism, CX3CR1 CRISPR, or selective CX3CR1 inhibitor AZD8797, was administer

Neuronal cathepsin S increases neuroinflammation and causes cognitive decline via CX3CL1-CX3CR1 axis and JAK2-… MEDIUM▼

Neuronal cathepsin S increases neuroinflammation and causes cognitive decline via CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway in aging and Alzheimer's disease.

Aging Cell · 2025 · PMID:39453382 · Q:0.59

ABSTRACT

Aging is an intricate process involving interactions among multiple factors, which is one of the main risks for chronic diseases, including Alzheimer's disease (AD). As a member of cysteine protease, cathepsin S (CTSS) has been implicated in inflammation across various diseases. Here, we investigated the role of neuronal CTSS in aging and AD started by examining CTSS expression in hippocampus neurons of aging mice and identified a significant increase, which was negatively correlated with recognition abilities. Concurrently, we observed an elevation of CTSS concentration in the serum of elderly people. Transcriptome and fluorescence-activated cell sorting (FACS) results revealed that CTSS overexpression in neurons aggravated brain inflammatory milieu with microglia activation to M1 pro-inflammatory phenotype, activation of chemokine C-X3-C-motif ligand 1 (CX3CL1)-chemokine C-X3-C-motif receptor 1 (CX3CR1) axis and janus kinase 2 (JAK2)-signal transducer and activator of transcription 3

Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary Atresia. MEDIUM

Cell · 2020 · PMID:33248023 · Q:0.59

ABSTRACT

Biliary atresia (BA) is a severe cholangiopathy that leads to liver failure in infants, but its pathogenesis remains to be fully characterized. By single-cell RNA profiling, we observed macrophage hypo-inflammation, Kupffer cell scavenger function defects, cytotoxic T cell expansion, and deficiency of CX3CR1+effector T and natural killer (NK) cells in infants with BA. More importantly, we discovered that hepatic B cell lymphopoiesis did not cease after birth and that tolerance defects contributed to immunoglobulin G (IgG)-autoantibody accumulation in BA. In a rhesus-rotavirus induced BA model, depleting B cells or blocking antigen presentation ameliorated liver damage. In a pilot clinical study, we demonstrated that rituximab was effective in depleting hepatic B cells and restoring the functions of macrophages, Kupffer cells, and T cells to levels comparable to those of control subjects. In summary, our comprehensive immune profiling in infants with BA had educed that B-cell-modifying

CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. MEDIUM

Pharmacol Ther · 2022 · PMID:34492237 · Q:0.33

ABSTRACT

Neuroinflammation was initially thought of as a consequence of neurodegenerative disease pathology, but more recently it is becoming clear that it plays a significant role in the development and progression of disease. Thus, neuroinflammation is seen as a realistic and valuable therapeutic target for neurodegeneration. Neuroinflammation can be modulated by neuron-glial signaling through various soluble factors, and one such critical modulator is Fractalkine or C-X3-C Motif Chemokine Ligand 1 (CX3CL1). CX3CL1 is produced in neurons and is a unique chemokine that is initially translated as a transmembrane protein but can be proteolytically processed to generate a soluble chemokine. CX3CL1 has been shown to signal through its sole receptor CX3CR1, which is located on microglial cells within the central nervous system (CNS). Although both the membrane bound and soluble forms of CX3CL1 appear to interact with CX3CR1, they do seem to have different signaling capabilities. It is believed that

CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis. MEDIUM

Int J Mol Sci · 2024 · PMID:38731899 · Q:0.44

ABSTRACT

The chemotactic cytokine fractalkine (FKN, chemokine CX3CL1) has unique properties resulting from the combination of chemoattractants and adhesion molecules. The soluble form (sFKN) has chemotactic properties and strongly attracts T cells and monocytes. The membrane-bound form (mFKN) facilitates diapedesis and is responsible for cell-to-cell adhesion, especially by promoting the strong adhesion of leukocytes (monocytes) to activated endothelial cells with the subsequent formation of an extracellular matrix and angiogenesis. FKN signaling occurs via CX3CR1, which is the only known member of the CX3C chemokine receptor subfamily. Signaling within the FKN-CX3CR1 axis plays an important role in many processes related to inflammation and the immune response, which often occur simultaneously and overlap. FKN is strongly upregulated by hypoxia and/or inflammation-induced inflammatory cytokine release, and it may act locally as a key angiogenic factor in the highly hypoxic tumor microenvironme

Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects in microglia. MEDIUM

Biochem Biophys Res Commun · 2026 · PMID:41924777 · Q:0.33

ABSTRACT

CX3CR1-Cre mouse lines have produced important advancements in our understanding of microglial biology. Recent studies have demonstrated the adverse effects of tamoxifen-induced CX3CR1-Cre expression during development, which may include changes in microglial density, phenotype, and DNA damage, as well as anxiety-like behavior. However, the unintended effects of constitutive CX3CR1-BAC-Cre expression remain unexplored. Here, we characterized the effects of CX3CR1-BAC-Cre expression on microglia in CX3CR1-BAC-Cre +/- and CX3CR1-BAC-Cre-/- male and female littermates during early postnatal development and adulthood in multiple brain regions. Additionally, we performed anxiety-like behavior tests to assess changes caused by Cre expression. We found that CX3CR1-BAC-Cre expression causes subtle region-and sex-specific changes in microglial density, volume, and morphology during development, but these changes normalized by adulthood in all brain regions except the hippocampus. No behavioral

Microglia-glioblastoma crosstalk mediates glioblastoma invasion at the far infiltration zone. MEDIUM

Immunity · 2026 · PMID:41923645 · Q:0.33

ABSTRACT

Glioblastoma (GB) cells infiltrate the brain parenchyma and colonize distant regions, driving recurrence and therapy resistance. Here, we examined dynamic microglial responses to infiltrating tumor cells during GB progression. Three-photon imaging in an autochthonous, immunocompetent GB mouse model enabled visualization of microglia-GB interactions at the far infiltration zone (FIZ) in the corpus callosum (CC). GB infiltration speed varied by anatomical location and tumor microtube (TM) number. Microglia increased surveillance in sparsely infiltrated areas but reduced it with higher GB density, revealing a biphasic response. Directional migration toward GB cells was restricted to microglial subsets within a defined spatial range, indicating heterogeneous reactivity. CX3CR1 deficiency enhanced microglial reactivity while limiting GB cell migration. Microglia depletion with the CSF1R inhibitor PLX5622 reduced GB cell migration and constrained TM plasticity. Thus, microglia respond to GB

Identification of suicide brain transcriptomic signatures using meta-analysis of multiple cohorts. MEDIUM

Transl Psychiatry · 2026 · PMID:41916959 · Q:0.50

ABSTRACT

Suicide remains a critical global public health issue, accounting for nearly one million deaths annually and imposing profound societal and economic burdens. Despite its urgency, the lack of diagnostic and predictive biomarkers continues to hinder the development of effective prevention and treatment strategies. This study presents a comprehensive meta-analysis that integrates publicly available postmortem brain transcriptomic datasets and a domestic cohort, encompassing 16 cohorts. The transcriptomic data, sourced from the Gene Expression Omnibus repository, were generated using various techniques, including traditional RNA sequencing, microarray methods, and single-cell RNA sequencing. Differential expression analyses were performed across multiple brain regions, with meta-analyses stratified by cortical regions, the dorsolateral prefrontal cortex (DLPFC), and combined. We further analyzed whether covariates may affect the identified genes. Three meta-analytic approaches were employe

G-protein coupled receptor chemokine CX3CR1 influences extracellular Tau internalization in Alzheimer's diseas… MEDIUM▼

G-protein coupled receptor chemokine CX3CR1 influences extracellular Tau internalization in Alzheimer's disease.

Adv Protein Chem Struct Biol · 2026 · PMID:41904008 · Q:0.33

ABSTRACT

Alzheimer's Disease is characterized by significant alterations in the cytoskeleton, driven by hyperphosphorylation of the microtubule-associated protein Tau. This modification impairs Tau's ability to stabilize microtubules, leading to structural instability, disrupted axonal transport, and neuronal degeneration. Hyperphosphorylated Tau aggregates into neurofibrillary tangles and oligomers, exacerbating cellular dysfunction. The cytoskeleton, composed of actin filaments, microtubules, and intermediate filaments, is vital for maintaining cellular structure, intracellular transport, and signalling. G-protein coupled receptors, widely expressed in neuroglial cells, play critical roles in neuroinflammation, synaptic pruning, and cytoskeletal dynamics in neurodegenerative diseases. Extracellular Tau species interact with GPCRs, particularly in microglia and astrocytes, triggering neuroinflammatory responses and cytoskeletal remodelling. Key kinases such as Glycogen Synthase Kinase-3β and C

Conserved ductular reaction mechanisms in biliary atresia and PSC derived from single-cell and spatial transcr… MEDIUM▼

Conserved ductular reaction mechanisms in biliary atresia and PSC derived from single-cell and spatial transcriptomics.

Cell Mol Gastroenterol Hepatol · 2026 · PMID:41903685 · Q:0.33

ABSTRACT

Primary sclerosing cholangitis (PSC) and biliary atresia (BA) both demonstrate the ductular reaction (DR), including biliary ductules, immune infiltration, and fibroblast activation. Advances in single-cell RNA sequencing and spatial transcriptomics have revolutionised our understanding of the DR fibro-inflammatory niche of these disorders. Recent studies using these techniques have also demonstrated that there are conserved mechanisms of fibro-inflammation across diseases and organ systems. Notably, epithelial, mesenchymal, and innate immune processes in the DR are shared between BA and PSC, including: pro-fibrogenic hepatocyte-to-cholangiocyte transdifferentiation, increased cholangiocyte senescence, accumulation of scar-/lipid-associated macrophages, Kupffer cell dysfunction, and activation of portal fibroblasts. In contrast, adaptive immune processes differ between the two disorders, including: transdifferentiation of Th17 into Th1 cells in BA, dominance of the Th17 axis in PSC, re

Identifies immunological mechanisms of neuroprotection in Parkinson's disease, suggesting relevance of microgl… MODERATE▼

Identifies immunological mechanisms of neuroprotection in Parkinson's disease, suggesting relevance of microglial modulation.

Front Aging Neurosci · 2026 · PMID:41788408 · Q:0.33

ABSTRACT

1. Front Aging Neurosci. 2026 Feb 18;18:1764634. doi: 10.3389/fnagi.2026.1764634. eCollection 2026. Systems-level molecular and immunological evidence identifies Th17/Treg modulation as a key...

Directly discusses chemokine networks and blood-brain barrier regulation, closely aligned with fractalkine axi… STRONG▼

Directly discusses chemokine networks and blood-brain barrier regulation, closely aligned with fractalkine axis hypothesis.

Biomolecules · 2026 · PMID:41897331 · Q:0.33

ABSTRACT

1. Biomolecules. 2026 Mar 5;16(3):395. doi: 10.3390/biom16030395. Chemokine Networks in Blood-Brain Barrier Regulation: Bidirectional Mechanisms, Clinical Translation, and Precision Therapeutic...

Directly examines CX3CL1/CX3CR1 axis dysregulation in neurological disorder, strongly supporting hypothesis. STRONG

Acta Neuropathol Commun · 2026 · PMID:41863015 · Q:0.33

ABSTRACT

1. Acta Neuropathol Commun. 2026 Mar 20. doi: 10.1186/s40478-026-02274-2. Online ahead of print. CX3CL1/CX3CR1 axis dysregulation contributes to epileptogenic mechanisms in focal cortical...

[Corrigendum] Influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism.

Int J Mol Med · 2026 · PMID:41930567 · Q:0.33

CX3CR1-T280M polymorphism and end-stage renal disease development in chronic kidney disease.

Sci Rep · 2026 · PMID:41932952 · Q:0.44

NIK-driven IL-23 production by myeloid cells is a key factor in the development of autoimmune inflammation.

J Exp Med · 2026 · PMID:41758203

Aging effects on emotionality, cognition and brain mononuclear cells in Sprague-Dawley rats of both sexes.

NPJ Aging · 2026 · PMID:41946716

CD8(+) T(EMRA) cells: A double-edged sword in immunity and disease-Mechanisms and therapeutic targets.

Int Immunopharmacol · 2026 · PMID:41946125

Expression of MS4A4A on synovial infiltrating macrophages is a hallmark of rheumatoid arthritis and reflects d…▼

Expression of MS4A4A on synovial infiltrating macrophages is a hallmark of rheumatoid arthritis and reflects disease severity.

Immunol Med · 2026 · PMID:41955527

Role of Cannabinoid Receptor Type 2 in Acute Behavioral Responses to Graft Versus Host Disease in Male Mice.

Cannabis Cannabinoid Res · 2026 · PMID:41958320

✗ Opposing Evidence 8

Error fetching MEDIUM

J Inflamm Res · 2022 · PMID:35642214 · Q:0.33

ABSTRACT

Microglia are tissue-resident macrophages of the central nervous system (CNS). In the CNS, microglia play an important role in the monitoring and intervention of synaptic and neuron-level activities. Interventions targeting microglia have been shown to improve the prognosis of various neurological diseases. Recently, studies have observed the activation of microglia in different cardiovascular diseases. In addition, different approaches that regulate the activity of microglia have been shown to modulate the incidence and progression of cardiovascular diseases. The change in autonomic nervous system activity after neuroinflammation may be a potential intermediate link between microglia and cardiovascular diseases. Here, in this review, we will discuss recent updates on the regulatory role of microglia in hypertension, myocardial infarction and ischemia/reperfusion injury. We propose that microglia serve as neuroimmune modulators and potential targets for cardiovascular diseases.

Microglia in neurodegeneration. MEDIUM

Nat Neurosci · 2018 · PMID:30258234 · Q:0.33

ABSTRACT

The neuroimmune system is involved in development, normal functioning, aging, and injury of the central nervous system. Microglia, first described a century ago, are the main neuroimmune cells and have three essential functions: a sentinel function involved in constant sensing of changes in their environment, a housekeeping function that promotes neuronal well-being and normal operation, and a defense function necessary for responding to such changes and providing neuroprotection. Microglia use a defined armamentarium of genes to perform these tasks. In response to specific stimuli, or with neuroinflammation, microglia also have the capacity to damage and kill neurons. Injury to neurons in Alzheimer's, Parkinson's, Huntington's, and prion diseases, as well as in amyotrophic lateral sclerosis, frontotemporal dementia, and chronic traumatic encephalopathy, results from disruption of the sentinel or housekeeping functions and dysregulation of the defense function and neuroinflammation. Pa

Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects in microglia MEDIUM

bioRxiv · 2024 · PMID:39554070 · Q:0.33

ABSTRACT

CX3CR1-Cre mouse lines have produced important advancements in our understanding of microglial biology. Recent studies have demonstrated the adverse effects of tamoxifen-induced CX3CR1-Cre expression during development, which include changes in microglial density, phenotype, and DNA damage, as well as anxiety-like behavior. However, the unintended effects of constitutive CX3CR1-BAC-Cre expression remain unexplored. Here, we characterized the effects of CX3CR1-BAC-Cre expression on microglia in CX3CR1-BAC-Cre+/- and CX3CR1-BAC-Cre-/- male and female littermates during early postnatal development and adulthood in multiple brain regions. Additionally, we performed anxiety-like behavior tests to assess changes caused by Cre expression. We found that CX3CR1-BAC-Cre expression causes subtle region- and sex-specific changes in microglial density, volume, and morphology during development, but these changes normalized by adulthood in all brain regions except the hippocampus. No behavioral effe

How neuroinflammation contributes to neurodegeneration. MEDIUM

Science · 2016 · PMID:27540165 · Q:0.58

ABSTRACT

Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal lobar dementia are among the most pressing problems of developed societies with aging populations. Neurons carry out essential functions such as signal transmission and network integration in the central nervous system and are the main targets of neurodegenerative disease. In this Review, I address how the neuron's environment also contributes to neurodegeneration. Maintaining an optimal milieu for neuronal function rests with supportive cells termed glia and the blood-brain barrier. Accumulating evidence suggests that neurodegeneration occurs in part because the environment is affected during disease in a cascade of processes collectively termed neuroinflammation. These observations indicate that therapies targeting glial cells might provide benefit for those afflicted by neurodegenerative disorders.

CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. MEDIUM

Pharmacol Ther · 2022 · PMID:34492237 · Q:0.33

ABSTRACT

G-protein coupled receptor chemokine CX3CR1 influences extracellular Tau internalization in Alzheimer's diseas… MEDIUM▼

G-protein coupled receptor chemokine CX3CR1 influences extracellular Tau internalization in Alzheimer's disease.

Adv Protein Chem Struct Biol · 2026 · PMID:41904008 · Q:0.33

ABSTRACT

Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets. MEDIUM

Int J Mol Sci · 2025 · PMID:41465422 · Q:0.44

ABSTRACT

Astrocytes and microglia constitute nearly half of all central nervous system cells and are indispensable for its proper function. Both exhibit striking morphological and functional heterogeneity, adopting either neuroprotective (A2, M2) or proinflammatory (A1, M1) phenotypes in response to cytokines, pathogen-associated molecular patterns (PAMPs)/damage-associated molecular patterns (DAMPs), toll-like receptor 4 (TLR4) activation, and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome signaling. Crucially, many of these phenotypic transitions arise during the earliest stages of neurodegeneration, when glial dysfunction precedes overt neuronal loss and may act as a primary driver of disease onset. This review critically examines glial-centered hypotheses of neurodegeneration, with emphasis on their roles in early disease phases: (i) microglial polarization from an M2 neuroprotective state to an M1 proinflammatory state; (ii) NLRP3 inflammasome assembly via P2X puri

CX3CR1: a potential microglia-specific PET imaging target in Alzheimer's and Parkinson's diseases. MEDIUM

Front Pharmacol · 2025 · PMID:41424797 · Q:0.33

ABSTRACT

Microglia are the resident immune cells of the central nervous system (CNS), playing a crucial role in maintaining brain homeostasis and mediating neuroimmune responses. The chemokine receptor CX3CR1, predominantly expressed on microglia, regulates microglial function via interactions with its neuronal ligand CX3CL1. The CX3CR1-CX3CL1 signaling exhibits complex, context-dependent roles in neurodegenerative diseases. In Alzheimer's disease (AD) and Parkinson's disease (PD) animal models, CX3CR1 deficiency shows paradoxical outcomes, attenuating or exacerbating amyloid-β (Aβ) and tau pathologies in AD, while consistently worsening α-synuclein-induced neurodegeneration in PD. Although CX3CR1 emerges as a promising therapeutic and diagnostic target, its complex role in microglial dynamics remains incompletely understood. Positron emission tomography (PET) imaging provides a powerful, noninvasive method for investigating biological processes in vivo. There is an urgent need to develop and v

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-01 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease

Hypothesis 1: Complement C1q Mimetic Decoy Therapy

Description: Engineer synthetic C1q mimetics that bind to synaptic "eat-me" signals without activating downstream complement cascade, effectively saturating microglial recognition sites and preventing pathological synaptic elimination. These decoys would competitively inhibit authentic C1q binding while lacking the Fc-like domain necessary for microglial phagocytosis activation.

Target: C1Q complement component subunit A (C1QA) and microglial compleme

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses

Hypothesis 1: Complement C1q Mimetic Decoy Therapy

Specific Weaknesses:

Selectivity Problem: C1q has essential physiological roles beyond synaptic pruning, including pathogen clearance and apoptotic cell removal. Broad C1q inhibition could compromise immune function and debris clearance.
Dosing Paradox: The therapeutic window may be extremely narrow - insufficient decoy concentration won't compete effectively, while excess may trigger non-specific immune responses.
Structural Complexity: C1q is a massiv

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment: Synaptic Pruning Therapeutics

Hypothesis 1: Complement C1q Mimetic Decoy Therapy

Revised Confidence: 0.45

Druggability Assessment

Target Class: Protein-protein interaction (PPI) - historically challenging but increasingly tractable Chemical Matter:

Large molecule approach: Engineered proteins/peptides mimicking C1q globular heads (22 kDa each)
Small molecule approach: PPI inhibitors targeting C1q-CR3 interface (challenging given large interaction surface ~1,500 Ų)
Best bet: Antibody-based decoys or engineered protein f

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↘

Falling

7d Momentum

▼ 26.2%

Volatility

Medium

0.0494

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
⚖	Recalibrated	$0.563	▲ 6.1%	calibrate_stale_price_his	2026-04-26 13:47
📄	New Evidence	$0.531	▲ 1.7%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.522	▲ 3.8%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.503	▼ 2.5%		2026-04-12 05:13
⚖	Recalibrated	$0.515	▲ 3.3%		2026-04-10 19:56
⚖	Recalibrated	$0.499	▼ 1.1%		2026-04-10 15:58
⚖	Recalibrated	$0.505	▲ 1.3%		2026-04-10 15:53
⚖	Recalibrated	$0.498	▼ 1.6%		2026-04-08 18:39
⚖	Recalibrated	$0.506	▼ 0.5%		2026-04-06 04:04
⚖	Recalibrated	$0.508	▼ 0.7%		2026-04-04 16:38
⚖	Recalibrated	$0.512	▲ 0.4%		2026-04-04 16:02
📄	New Evidence	$0.509	▲ 1.8%	evidence_batch_update	2026-04-04 09:08
⚖	Recalibrated	$0.501	▼ 14.6%		2026-04-03 23:46
⚖	Recalibrated	$0.586	▲ 8.5%	market_dynamics	2026-04-03 01:06
⚖	Recalibrated	$0.540	▲ 1.1%	market_dynamics	2026-04-03 01:06

Clinical Trials (4) Relevance: 13%

2
Active

2
Completed

0
Total Enrolled

Phase II
Highest Phase

ANX005 (Anti-C1q) in Huntington's Disease Phase II

Recruiting · NCT03999515

AL003 (Anti-SIGLEC-3/CD33) in Alzheimer's Phase I

Completed · NCT04777396

Daratumumab (Anti-CD38) in Alzheimer's Phase II

Recruiting · NCT04592874

Emtricitabine (NRTI) for Neuroinflammation Phase I

Completed · NCT03943264

📚 Cited Papers (77)

How neuroinflammation contributes to neurodegeneration.

Science (2016) · PMID:27540165

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Microglia in neurodegeneration.

Nat Neurosci (2018) · PMID:30258234

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets.

International journal of molecular sciences (2025) · PMID:41465422

5 figures

Figure 1

Hypothesis of microglial polarization from the M2 to M1 phenotype and NLRP3 inflammasome activation. Panel ( A ) In the APP/PS1 mouse model of Alzheimer’s disease, microglia initia...

pmc_api

Figure 2

Hypothesis of crosstalk among microglia, astrocytes, and neurons. Panel schematic on the ( right ). An M1 polarized microglial cell releases proinflammatory mediators that act on A...

pmc_api

Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.

J Inflamm Res (2022) · PMID:35642214

2 figures

Figures

Figures available at source paper (no open-access XML found).

deep_link

Figures

Figures available at source paper (no open-access XML found).

deep_link

CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.

Pharmacol Ther (2022) · PMID:34492237

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Visual representations by cortical somatostatin inhibitory neurons--selective but with weak and delayed responses.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2010) · PMID:20980594

No extracted figures yet

Synaptic pruning by microglia is necessary for normal brain development.

Science (New York, N.Y.) (2011) · PMID:21778362

No extracted figures yet

Specific profile of tau isoforms in argyrophylic grain disease.

Journal of experimental neuroscience (2013) · PMID:25157208

No extracted figures yet

The Role of Functional Imaging in Radiotherapy Planning and Management for Gynecologic Malignancies.

PET clinics (2011) · PMID:27156590

No extracted figures yet

How neuroinflammation contributes to neurodegeneration.

Science (2016) · PMID:27540165

No extracted figures yet

Ni Foam-Ni

Chemistry (Weinheim an der Bergstrasse, Germany) (2017) · PMID:28133889

No extracted figures yet

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.

Cell reports (2018) · PMID:30021162

No extracted figures yet

📙 Related Wiki Pages (15)

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Synaptic pruning by microglia in early AD — Analysis Notebook

CI-generated notebook stub for analysis sda-2026-04-01-gap-v2-691b42f1. Synaptic pruning by microglia in early Alzheimer's disease (AD) involves the elimination of synapses, a process that is normally …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

High Efficiency Resource Efficiency Score

0.84

60.6th percentile (776 hypotheses)

Tokens Used

8,978

KG Edges Generated

1,282

Citations Produced

Cost Ratios

Cost per KG Edge

115.10 tokens

Lower is better (baseline: 2000)

Cost per Citation

264.06 tokens

Lower is better (baseline: 1000)

Cost per Score Point

13380.03 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.084

10% weight of efficiency score

Adjusted Composite

0.647

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-17T09:10	$0.669	0.557

Wiki Pages

KG Entities (35)

ANXA1 C1Q C1QA COGNITIVE DECLINE CX3CR1 DAP12 Fractalkine receptor / microglia-neuron GSDMD HK2 Microglial activation / TREM2 signaling NLRP3 P2RY12 P38 PI3K SOD1 SYNAPTIC PRUNING Synaptic function / plasticity TREM2 TREM2-DAP12 microglial signaling eat_me_signals

Dependency Graph (1 upstream, 4 downstream)

Depends On

Microglial Purinergic Reprogrammingbuilds_on (1.0)

Depended On By

TREM2-mediated microglial tau clearance enhancementbuilds_on (1.0)Purinergic P2Y12 Inverse Agonist Therapybuilds_on (1.0)TREM2 Conformational Stabilizers for Synaptic Discriminationbuilds_on (0.6)Optogenetic Microglial Deactivation via Engineered Inhibitory Opsinsrefines (0.5)

Linked Experiments (9)

TREM2 Function in Alzheimer's Disease — From Risk Variant to Therapeutic Targetvalidation | tests | 0.45 TREM2 Agonist Therapy for Parkinson's Disease — Experimental Designvalidation | tests | 0.45 Microglial TREM2 Agonist In Vivo Efficacyvalidation | tests | 0.45 s:** - GPR32 knockout in microglia should worsen neuroinflammation if this is thfalsification | tests | 0.40 Proposed experiment from debate on Synaptic pruning by microglia in early ADfalsification | tests | 0.40 Microglial Contributions to Huntington's Disease Pathogenesisvalidation | tests | 0.40 Microglial Aging and Immune Memory in Neurodegeneration — Training the Brain's Mvalidation | tests | 0.40 DLB Treatment Response Biomarkers — Predicting Cholinesterase Inhibitor Responseclinical | tests | 0.40 FTD Microglia Role: Protective vs Destructive Mechanism Studyvalidation | tests | 0.40

Related Hypotheses

Microglia-Mediated Synaptic Pruning Modulation to Optimize Functional Connectome Efficiency

Score: 0.000 | connectomics

Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins

Score: 0.655 | neurodegeneration

CX3CR1 Promoter Methylation Disrupts Neuron-Microglia Cross-Talk

Score: 0.649 | developmental neurobiology

CX3CR1 Agonism Enhances Microglial Phagocytosis of Extracellular Tau Seeds, Preventing Template-Dependent Misfolding

Score: 0.630 | neurodegeneration

CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping

Score: 0.477 | biomarkers

Estimated Development

Estimated Cost

Timeline

2.3 years

🧪 Falsifiable Predictions (5)

5 total 0 confirmed 0 falsified

sufficient vs C1q-deficient AD mice 2. Measure systemic immune function (bacterial clearance, autoantibody formation) during chronic decoy treatment 3. Examine whether decoys prevent beneficial C1q functions like amyloid phagocytosis

pending conf: 0.60